Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria | Synapse
April 4, 2026Open Access
Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria
Key Points
The study aims to determine if ctDNA-derived tumor metrics improve risk stratification for HR-positive/HER2-negative advanced breast cancer.
Conducted a multicenter cohort study across multiple institutions in Austria.
Analyzed baseline ctDNA-derived tumor metrics alongside established clinical variables.
Employed statistical methods to compare risk stratification improvements.
Integration of ctDNA metrics significantly enhanced risk stratification.
Improved accuracy in identifying patients at higher risk for disease progression.
Demonstrated utility of ctDNA metrics in clinical decision-making for advanced breast cancer patients.
Abstract
Our findings demonstrate that integrating baseline ctDNA-derived TFx metrics with established clinical variables significantly improves risk stratification in HR-positive/HER2-negative ABC.